

Publikationsliste von Aram Prokop

Stand 2022.08.

Full paper

1. **Prokop, A.**, Wieder, T., Sturm, I., Eßmann, F., Seeger, K., Wuchter, C., Ludwig, W.-D., Henze, G., Dörken, B., and Daniel, P.T., Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2- ratio and loss of spontaneous caspase-3 processing in vivo, *Leukemia*, **2000**, 14: 1606-1613.
2. Wieder, Th., Eßmann, F., **Prokop, A.**, Schmelz, K., Schulze-Osthoff, K., Beyaert, R., Dörken, B., and Daniel, P. T.; Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3, *Blood*, **2001**,97: 1378- 1387.
3. Wieder, T., **Prokop, A.**, Bagci, B., Essmann, F., Bernicke, D., Schulze-Osthoff, K., Dörken, B., Schmalz, H.G., Daniel, P.T. and Henze, G.; Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary leukemic lymphoblasts. *Leukemia*, **2001**, 15: 1735-42.
4. **Prokop, A.**, Wrasidlo, W., Lode, L., Herold, R., Lang, F., Henze, G., Dörken, B., Wieder, T. and Daniel, P. T., Induction of apoptosis by enediyne antibiotic calicheamicin 9II proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. *Oncogene*, **2003**, 22 (57): 9107-20.
5. Schlawe, D., Majdalani, A., Velcicky, J., Heßler, E., Wieder*, T., **Prokop, A.***, and Schmalz, H-G.*. Iron-containing nucleoside analogs with pronounced apoptosis-inducing activity. *Angewandte Chemie*, **2004**, 116, 1763-1766
6. Velcicky, J., Lanver, A., Lex, J., **Prokop, A.***, Wieder, T.*, Schmalz, H.-G.*. Transition-Metal-Mediated Synthesis of Novel Carbocyclic Nucleoside Analogues with Antitumoral Activity. *Chem. Eur. J.* **2004**, 10, 5087-5110.
7. Diller, R. A., Riepl, H. M., Rose, O. Frias, C., Henze, G. and **Prokop, A.**, Synthesis of demethylxanthohumol, a new potent apoptosis inducing agent from hops, *Chemistry &*

Biodiversity, **2005**, 2: 1331-1338

8. James, P., **Prokop, A.***, Neudörfl, J., Eißmann, M., Jesse, P., Henze, G., and Schmalz*, H.-G., Enantioselective Synthesis of Ferrocenyl Nucleoside Analogs with Apoptosis-Inducing Activity, *Org. Lett.*, **2006**, 13: 2763-2766
9. Shults, E.E., J. Velder, J., Schmalz, H.-G., Chernov, S.V., Rubalova, T.V., Gatilov, Y.V., Henze, G., Tolstikov, G.A., and **Prokop, A.**, Gram-scale synthesis of pinusolide and its antileukemic potential, *BMCL*, **2006**, 16: 4228 - 4232
10. Diller, R.A., Riepl, H.M., Rose, O., Frias, C., Henze, G., and **Prokop, A.**, Ability of Prenylflavanones present in hops to induce apoptosis in a mitochondrial dependent manner in human Burkitt Lymphoma cell line BJAB, *Plant. Med.*, **2007**, 73: 755-761
11. Seifert, G., Jesse, P., Laengler, A., Reindl, T., Lüth, M. Lobitz, S., Henze, G., **Prokop*, A.**, Lode* H. N. Molecular mechanisms of Mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro, *Cancer Letters*, **2008**, 264: 218-228
12. Gansäuer, A., Winkler, I., Worgull, D., Lauterbach, T., Franke, D., Selig, A., Wagner, L., **Prokop, A.**; Carbonyl-substituted Titanocenes: A novel class of cytostatic compounds with high antitumor and antileukemic activity. *Chemistry Eur. J.*, **2008**, 14: 4160-4163
13. Meggers, E., Atilla-Gokcumen, G.E., Gründler, K., Frias, C., and **Prokop, A.**; Inert Ruthenium Half-Sandwich Complexes with Anticancer Activity; *Dalton Transactions*, **2009**, 48:10882-10888
14. Nicolaus, N., Strauss, S., Neudörfl, J.M., **Prokop, A.**, Schmalz, H.G.; A [2 + 2 + 2]-cycloaddition approach toward 6-oxa-allocolchicinoids with apoptosis-inducing activity. *Org Lett.*; **2009**, 11(2):341-344
15. Ott, I., Qian, X., Xu, Y., Vlecken, D.H., Marques, I.J., Kubutat, D., Will, J., Sheldrick, W.S., Jesse, P., **Prokop, A.**, Bagowski, C.P.; A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. *J Med Chem.*, **2009**, 53: 763-770
16. Dobroschke, M., Geldmacher, Y., Ott, I., Harlos, M., Kater, L., Wagner, L., Gust, R., Sheldrick, W.S., **Prokop, A.**; Cytotoxic rhodium(III) and iridium(III) polypyridyl complexes:

structure-activity relationships, antileukemic activity, and apoptosis induction. *ChemMedChem.*; **2009**, 4(2):177-187

17. Jesse, P., Mottke, G., Eberle, J., Seifert, G., Henze, G., **Prokop, A.**; Apoptosis-inducing activity of *Helleborus niger* in ALL and AML. *Pediatr Blood Cancer.*; **2009**, 52(4):464-469

18. Bieda, R., Ott, I., Dobroschke, M., **Prokop, A.**, Gust, R., Sheldrick, W.S.; Structure-activity relationships and DNA binding properties of apoptosis inducing cytotoxic rhodium(III) polypyridyl complexes containing the cyclic thioether [9]aneS(3). *J Inorg Biochem.*, **2009**, 103(5):698-708

19. Bernt, K.M., **Prokop, A.**, Huebener, N., Gaedicke, G., Wrasidlo, W., Lode, H.N.; Eradication of CD19+ leukemia by targeted calicheamicin θ . *Bioconjug Chem.*; **2009**, 20(8):1587-1594

20. Meggers, E., Atilla-Gokcumen, G.E., Gründler, K., Frias, C., **Prokop, A.**; Inert ruthenium half-sandwich complexes with anticancer activity. *Dalton Trans.*; **2009**, (48):10882-10888

21. Lee, S.Y., Peckermann, I., Abinet, E., Okuda, J., Henze, G., **Prokop, A.**; The rare-earth yttrium complex [YR(mtbmp)(thf)] triggers apoptosis via the extrinsic pathway and overcomes multiple drug resistance in leukemic cells. *Med Oncol.* **2010**

22. Rubbiani, R., Kitanovic, I., Alborzinia, H., Can, S., Kitanovic, A., Onambele, L.A., Stefanopoulou, M., Geldmacher, Y., Sheldrick, W.S., Wolber, G., **Prokop, A.**, Wölfl, S., Ott, I.; Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. *J Med Chem.*; **2010**, 53(24):8608-8618

23. Lee, S.Y., Hille, A., Frias, C., Kater, B., Bonitzki, B., Wölfl, S., Scheffler, H., **Prokop, A.**, Gust, R.; [NiII(3-OMe-salophene)]: a potent agent with antitumor activity. *J Med Chem.*; **2010**, 53(16):6064-6070

24. Bieda, R., Dobroschke, M., Triller, A., Ott, I., Spehr, M., Gust, R., **Prokop, A.**, Sheldrick, W.S.; Cell-selective, apoptosis-inducing rhodium(III) crown thiaether complexes. *ChemMedChem.*; **2010**, 5(7):1123-1133

25. Nicolaus, N., Zapke, J., Riesterer, P., Neudörfl, J.M., **Prokop, A.**, Oschkinat, H.,

Schmalz, H.G.; Azides derived from colchicine and their use in library synthesis: A practical entry to new bioactive derivatives of an old natural drug. *ChemMedChem.*; **2010**, 5(5):661-665

26. Franke, J.C., Plötz, M., **Prokop, A.**, Geilen, C.C., Schmalz, H.G., Eberle, J.; New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue. *Biochem Pharmacol.*, **2010**; 79(4):575-586.

27. Splith, K., Hu, W., Schatzschneider, U., Gust, R., Ott, I., Onambele, L.A., **Prokop, A.**, Neundorff, I.; Protease-activatable organometal-Peptide bioconjugates with enhanced cytotoxicity on cancer cells. *Bioconjug Chem.*, **2010**; 21(7):1288-1296.

28. Mulcahy, S.P., Gründler, K., Frias, C., Wagner, L., **Prokop, A.**, Meggers, E.; Discovery of a strongly apoptotic ruthenium complex through combinatorial coordination chemistry. *Dalton Trans.*, **2010**; 39(35): 8177-8182.

29. Kater, B., Hunold, A., Schmalz, H.G., Kater, L., Bonitzki, B., Jesse, P., **Prokop, A.**; Iron containing anti-tumoral agents: unexpected apoptosis-inducing activity of a ferrocene amino acid derivative. *J Cancer Res Clin Oncol.*, **2010**

30. Lee, S.Y., Hille, A., Kitanovic, I., Jesse, P., Henze, G., Wöfl, S., Gust, R., **Prokop, A.** [Fe(III)(salophene)Cl], a potent iron salophene complex overcomes multiple drug resistance in lymphoma and leukemia cells. *Leuk Res.*, **2010**

31. He, X., Gong, L., Kräling, K., Gründler, K., Frias, C., Webster, R.D., Meggers, E., **Prokop, A.**; Xia H.; Unusual eta²-allene osmacycle with apoptotic properties. *ChemBiochem.*, **2010**; 11(11): 1607-1613.

32. Onambele, L.A., Koth, D., Czaplowska, J.A., Schubert, U.S., Görls, H., Yano, S., Obata, M., Gottschaldt, M., **Prokop, A.**; Mitochondrial mode of action of a thymidine-based cisplatin analogue breaks resistance in cancer cells. *Chemistry.*, **2010**; 16(48):14498-14505.

33. Kausch-Busies, N., Neudörfl, J.M., **Prokop, A.**, and Schmalz, H.G.; Synthesis and First Biological Evaluation of an Iron-Containing HETE-Analogue. *Eur. J.Org. Chem.* **2011**, 1133-1139.

34. Kausch-Busies, N., Neudörfl, J.-M., Wefelmeier, P., **Prokop, A.**, Kühn, H., Schmalz, H.-G.; Stereoselective Synthesis and Biological Evaluation of Ferrocene-Containing, HETE-

Analogs. *Eur. J. Org. Chem.*, **2011**, 24: 4634-4644.

35. Geldmacher, Y., Rubbiani, R., Wefelmeier, P., **Prokop, A.**, Ott, I., Sheldrick, W.S.; Synthesis and DNA-binding properties of apoptosis-inducing cytotoxic half-sandwich rhodium(III) complexes with methyl-substituted polypyridyl ligands. *Journal of Organometallic Chemistry*, **2011**, 696: 1023-1031

36. Geldmacher, Y., Kitanovic, I., Alborzina, H., Bergerhoff, K., Rubbiani, R., Wefelmeier, P., **A. Prokop**, R. Gust, I. Ott, S. Wölfl, W. S. Sheldrick; Cellular Selectivity and Biological Impact of Cytotoxic Rhodium(III) and Iridium(III) Complexes Containing Methyl-substituted Phenanthroline Ligands. *ChemMedChem*, **2011**, 6: 429-439.

37. Kater, L., Claffey, J., Hogan, M., Jesse, P., Kater, B., Strauss, S., Tacke, M., **A. Prokop**; The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming multiple drug resistance in malignant leukemia cells. *Toxicol In Vitro*, **2011**, 26(1):119-124.

38. Streiter, M., Malecki, M., **Prokop, A.**, Schildgen, V., Lüsebrink, J., Guggemos, A., Wisskirchen, M., Weiss, M., Cremer, R., Brockmann, M., Schildgen, O.; Does human bocavirus infection depend on helper viruses? A challenging case report. *Virol J.*, **2011**; 8:417.

39. Wild, A., Babiuch, K., König, M., Winter, A., Hager, M.D., Gottschaldt, M., **Prokop, A.**, Schubert, U.S.; Synthesis of a glycopolymeric Pt(II) carrier and its induction of apoptosis in resistant cancer cells. *Chem Commun (Camb)*, **2012**

40. Geldmacher, Y., Splith, K., Kitanovic, I., Alborzina, H., Can, S., Rubbiani, R., Nazif, M.A., Wefelmeier, P., **Prokop, A.**, Ott, I., Wölfl, S., Neundorf, I., Sheldrick, W.S.; Cellular impact and selectivity of half-sandwich organorhodium(III) anticancer complexes and their organoiridium(III) and trichloridorhodium(III) counterparts. *J Biol Inorg Chem.*, **2012**, 17(4): 631-646

41. Köster, S. D., Alborzina, H., Can, S., Kitanovic, I., Wölfl, S., Rubbiani, R., Ott, I., Riesterer, P., **Prokop, A.**, Merz, K., Metzler-Nolte, N.; A spontaneous gold(I)-azide alkyne

cycloaddition reaction yields gold-peptide bioconjugates which overcome cisplatin resistance in a p53-mutant cancer cell line; *Chem. Sci.*, **2012**, 3: 2062-2072.

42. Sitnikov, N., Velder, J., Abodo, L., Cuvelier, N., Neudörfl, J., **Prokop, A.**, Krause, G., Fedorov, A. Y., Schmalz, H.-G.; Total Synthesis of Indole-derived Allocolchicine Analogs Exhibiting Strong Apoptosis-inducing Activity; *Chem. Eur. J.*, **2012**, 18: 12096-12102.

43. Termath, A. O., Ritter, S., König, M., Kranz D. P., Neudörfl, J.- P., **Prokop, A.***, Schmalz, H.- G.; Sythesis of Oxa-B-Ring Analogs of Colchicine through Rh- Catyzed Intramolecular (5+2) Cycloaddition; *European Journal of Organic Chemistry*, **2012**, 24: 4501–4507

44. Beulertz, J., Bloch, W., **Prokop, A.**, Baumann, F.T.; Therapeutische Rahmenbedingungen von Bewegungsprogrammen in der pädiatrischen Onkologie. Erste Erfahrungen aus der Praxis. *Deutsche Zeitschrift für Onkologie*. **2012**; 44: 162-166.

45. Navakovski de Oliveira, K., Andermark, V., von Grafenstein, S., Onambele, L. A., Dahl, G., Rubbiani, R., Wolber, G., Gabbiani, C., Messori, L., **Prokop, A.**, Ott, I.; Butylin (IV) Benzoates: Inhibition of Thioredoxin reductase, Tumor Cell Growth Inhibition, and Interactions with Proteins; *Chem Med Chem*, **2013**, 2: 256- 264

46. Pfeiffer, H., Dragoun, M., **Prokop, A.**, Schatzschneider, U.; Biological Activity of Molybdenum(II) Allyl Dicarbonyl Complexes with N- N Coligands of Variable Aromatic Surface Area on Adherent and Non- adherent Human Cancer Cells, *Zeitschrift für anorganische und allgemeine Chemie*, **2013**, (8-9): 1568–1576

47. Beulertz, J., Bloch, W., Prokop, A., Baumann, F.T.; Specific deficit analyses in motor performance and quality of life of pediatric cancer patients--a cross-sectional pilot study; *Pediatr Hematol Oncol.*, **2013**, 30(4): 336-347.

48. Oehninger, L., Küster, L.N., Schmidt, C., Muñoz-Castro, A., **Prokop, A.**, Ott, I.; A Chemical–Biological Evaluation of Rhodium(I) N-Heterocyclic Carbene Complexes as Prospective Anticancer Drugs. *Chem. Eur. J.*, **2013**

49. Hirschhäuser, C., Velcicky, J., Schlawe, D., Hessler, E., Majdalani, A., Neudörfl, J.M.,

Prokop, A.*, Wieder, T., Schmalz, H.-G.; Nucleoside Analogues with a 1,3-Diene--Fe(CO)₃ Substructure: Stereoselective Synthesis, Configurational Assignment, and Apoptosis-Inducing Activity.; *Chemistry*. **2013**, 39: 13017-13029

50. Beulertz, J., Bloch, W., **Prokop, A.**, Baumann, F.T.; Zielgerichtete und individualisierte Bewegungstherapie in der pädiatrischen Onkologie – ein Pilotprojekt. *Monatsschrift Kinderheilkunde*. **2013**; 4: 330-335.

51. Beulertz, J., Bloch, W., **Prokop, A.**, Baumann, F.T. Specific deficit analyses in motor performance and quality of life of pediatric cancer patients – a controlled cross-sectional trial. *Pediatric hematology/oncology*. **2013**; 30(4): 336-47.

52. Kuznetsova, N. R., Svirshchevskaya, E. V., Sitnikov, N. S., Abodo, L., Sutorius, H., Zapke, J., Velder, J., Thomopoulou, P., Oschkinat, H., **Prokop, A.**, Schmalz, H.-G., Fedorov, Y. A., Vodovozova, E. L.; Lipophilic prodrugs of a triazole-containing colchicine analogue in liposomes: Biological effects on human tumor cells. *Russ. J. Bioorg. Chem.*, **2013**, 39: 543-552

53. Sitnikov, N. S., Kokisheva, A. S., Fukin, G. K., Neudörfl, J.-M., Sutorius, H., **Prokop, A.**, Fokin, V. V., Schmalz, H.-G., and Fedorov, A.Y.; Synthesis of Indole-Derived Alcolcolchicine Congeners through Pd-Catalyzed Intramolecular C-H Arylation Reaction. *Eur. J. Org. Chem.*, **2014**, 29, 6481–6492

54. Serebryanskaya, T.V., Lyakhov, A. S., Ivashkevich, L.S., Schur, J., Frias, C., **Prokop, A.**, and Ott. I.*; Gold(I) thiotetrazolates as thioredoxin reductase inhibitors and antiproliferative agents. *Dalton Transactions*, **2014**

55. Gansäuer, A., Okkel, A., Schwach, L., Wagner, L., Selig, A., **Prokop, A.**; Triazol-substituted titanocenes by strain-driven 1,3-dipolar cycloadditions, *BEILSTEIN J. ORG. CHEM.*, **2014**, 10, 1630-1637

56. De Oliveira, K. N., Andermark, V., Onambele, L. A., Dahl, G., **Prokop, A.** and Ott, I.; Organotin complexes containing carboxylate ligands with maleimide and naphthalimide derived partial structures: TrxR inhibition, cytotoxicity and activity in resistant cancer cells; *EUR. J. MED. CHEM.*, **2014**, 87, 794-800
57. Beulertz, J., Bloch, W., Rustler, V., Herich, L., Streckmann, F., Fitzen, C., **Prokop, A.**, Baumann, F.T.; Ankle Dorsiflexion Range of Motion and Gait in childhood cancer patients. *Cancer Nursing*, **2014**,
58. Hoell, J.I., Gombert, M., Ginzel, S., Loth, S., Landgraf, P., Käfer, V., Streiter, M., **Prokop, A.**, Weiss, M., Thiele, R., and Borkhardt, A.; Constitutional mismatch repair-deficiency and whole-exome sequencing as the means of the rapid detection of the causative MSH6 defect. *Klinische Pädiatrie* **2014**, 226(6-7): 357-61
59. Beulertz, J., Bloch, W., **Prokop, A.**, Herich, L., Baumann, F.T.; The effect of a six-month therapeutic exercise program on motor performance in childhood cancer patients. Study protocol of the ESCiMo-Study. *BMC Pediatrics*, **2014**
60. Abodo Onambele, L., Riepl, H., Fischer, R., Pradel, G., **Prokop, A.***, Aminake, M. N.; Synthesis and evaluation of the antiplasmodial activity of tryptanthrin derivatives. *International Journal for Parasitology*, **2015**, Drugs and drug resistance 5: 48 - 57
61. Yadav, D.B., Taleli, L., van der Westhuyzen, A.E., Fernandes, M.A., Dragoun, M., **Prokop, A.**, Schmalz, H.-G., de Koning, C.B., and Willem A. L. van Otterlo, W.A.L.; Synthesis of diverse 6-oxa-allocholchicinoids by a Suzuki-Miyaura coupling, acid-catalyzed-intramolecular-transacetalization strategy. *European Journal of Organic Chemistry*, **2015**
62. Prinz, C., Lohmann, G., Vasyutina, E., Romanski, S., Hirschhäuser, C., Mayer, P., Frias, C., Hallek, M., Schmalz, H.-G., **Prokop, A.**, Mougiakakos, D., Herling, M., Schrader, A., and Herling, C. D.; Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. *Molecular Cancer*, **2015**
63. Sitnikov, N.S., Sinzov, A.V., Allegro, D., Barbier, P., Onambele, L.A., **Prokop, A.**, Schmalz, H.-G., and Fedorov, A.Y.; Synthesis of indole-derived allocholchicine congeners

exhibiting pronounced anti proliferative and apoptosis inducing properties. *MedChemCommun*, **2015**

64. Beulertz, J. Rustler, V., **Prokop, A.** und Baumann, F.; Nebenwirkungen und Spätfolgen in der pädiatrischen Onkologie – Potentiale der Bewegungstherapie. *Onkologische Pharmazie*, **2016**, Nr. 1/2016 S. 10 – 14

65. Beulertz, J., Bloch, W., **Prokop, A.**, Rustler, V., Fitzen, C., Herich, L., Streckmann, F., Baumann, F.T. Limitations in Ankle Dorsiflexion Range of Motion, Gait, and Walking Efficiency in Childhood Cancer Survivors. *Cancer Nurs.*, **2016** Mar-Apr;39(2): 117-24.

66. Beulertz, J., **Prokop, A.**, Rustler, V., Bloch, W., Felsch, M., Baumann, F.T. Effects of a 6-Month, Group-Based, Therapeutic Exercise Program for Childhood Cancer Outpatients on Motor Performance, Level of Activity, and Quality of Life. *Pediatr Blood Cancer*, **2016**, 63(1):127-32

67. **Prokop, A.**, Czaplewska, J. A., Dobroschke, M., König, M., Wild, A., Thorwirth, R., Schulze, B., Babiuch, K., Pretzel, D., Schubert, U. S., and Gottschaldt, M.; Iridium(III) Complexes of Terpyridine- and Terpyridine-Analogous Ligands Bearing Sugar Residues and Their in vitro Activity. *Eur. J. of Inorganic Chem.*, **2016**, 3480-88

68. Streciwilk, W., Terenzi, A., Misgeld, R., Frias, C., Jones, P. G., **Prokop, A.**, Keppler, B., Ott, I.; Metal NHC Complexes with Naphthalimide Ligands as DNA-Interacting Antiproliferative Agents. *Chem.Med.Chem.*, **2017**, 12 (3): 214 - 225

69. Schmidt, C., Karge, B., Misgeld, R., **Prokop, A.**, Franke, R., Brønstrup, M., and Ott, I.; Gold(I) NHC Complexes: Antiproliferative Activity, Cellular Uptake, Inhibition of Mammalian and Bacterial Thioredoxin Reductases and Gram-Positive Directed Antibacterial Effects. *Eur. J. Chem.*, **2017**, 23 (8): 1869 - 1880

70. Schmidt, C., Karge, B., Misgeld, R., **Prokop, A.**, Brønstrup, M., and Ott, I.; Biscarbene gold(I) complexes: structure-activity-relationships regarding antibacterial effects, cytotoxicity, TrxR inhibition and cellular bioavailability. *Med. Chem. Commun.*, **2017**, 8 (8): 1681 - 1689

71. König, M., Siegmund, D., Raszeja, L.J., **Prokop, A.**, and Metzler-Nolte, N.; Resistance-breaking profiling and gene expression analysis on an organometallic ReI-phenanthridine complex reveal parallel activation of two apoptotic pathways. *Journal of Medicinal Chemistry*, **2017**, 9: 173-180
72. Rustler, V., **Prokop, A.**, Baumann, F., Streckmann, F., Bloch, W. , and Däggelmann, J.; Whole-body vibration training designed to improve functional impairments after pediatric inpatient anticancer therapy: A pilot study. *Pediatr. Phys. Ther*, **2018**, 30 (4): 341 – 349
73. Dragoun, M., Günther, T., Frias, C., Berkessel, A., **Prokop, A.**; Metal-free salan-type compound induces apoptosis and overcomes multidrug resistance in leukemic and lymphoma cells in vitro. *Journal of Cancer Research and Clinical Oncology*, **2018**, 144 (4): 685 - 695
74. Schmidt, C., Albrecht, L., Balasupramaniam, S., Misgeld, R., Karge, B., Brönstrup, M., **Prokop, A.**, Baumann, K., Reichl, S., and Ott, I.; A gold(I) biscarbene complex with improved activity as TrxR inhibitor and cytotoxic drug: comparative studies with different gold metallodrugs. *Metallomics*, 11(3): 533-545, **2019**
75. Krull, K., Kunstreich, M., Bronsema, A., Bleckmann, K., Classen, C.-F., Erdlenbruch, B., Jorch, N., Kolb, R., Leipold, A., **Prokop, A.**, Scheurlen, W., Steinbach, D., Weber, C., Klasen-Sansone, J., Klee, D., Escherich, G., Moericke, A., Schrappe, M., Borkhardt, A., and Kuhlen, M.; Osteonecrosis in children with ALL at initial diagnosis and prior to any chemotherapy. *Leukemia & Lymphoma*, 60(1):78-84, **2019**
76. Zernikow, B., Maaßen, K., Hübner-Möhler, B., Wager, J., Paulussen, M., Lassay, L., Jorch, N., Dilloo, D., Schneider, D., Janßen, G., Oommen, P.T., Kuhlen, M., Brune, T., Wieland, R., Kremens, B., Längler, A., **Prokop, A.**, Niehues, T., MD B. Köster, B., Rose, M., Baumann-Köhler, M., Irnich, M., Kiener, R., Sinha, K., Wolfe, J., and Schmidt, P.; Specialized pediatric palliative care services for children dying from cancer: developments of symptom management and quality of care over a 10-year period. *Journal of Palliative Medicine*, 33(3): 381-391, **2019**
77. Oswald, V., **Prokop, A.**, Böhme, J., Gressler, N., Harscheidt, F., Maas, V., Bloch, W., Baumann, F.T., Julia Daeggelmann, J.; Limited walking abilities and impaired ankle

dorsiflexion function in children after intense cancer treatment. *Klinische Pädiatrie*, 231: 142-149, **2019**

78. Grau, M., Jerke, M., Nader, E., Schenk, A., Renoux, C., Collins, B., Dietz, T., Bizjak, D. A., Joly, P., Bloch, W., Philippe Connes, P., and **Prokop, A.**; Effect of acute exercise on RBC deformability and RBC nitric oxide synthase signalling pathway in young sickle cell anaemia patients. *Scientific reports*, **2019**, 9: 11813

79. Grau, M., Nader, E., Jerke, M., Schenk, A., Renoux, C., Dietz, T., Collins, B., Bizjak, D., Joly, P., Bloch, W., **Prokop, A.**, Connes, P.; Impact of a six-week training program on ventilatory efficiency, red blood cell rheological parameters and red blood cell nitric oxide signaling in young sickle cell anemia patients. *Journal of Clinical Medicine*, **2019**, 8: 2155

80. Kunz, JB., Lobitz, S., Grosse, R., Oevermann L., Hakimeh, D., Jarisch, A., Cario, H., Beier, R., Schenk, D., Schneider, D., Groß-Wieltsch, U., **Prokop, A.**, Heine, S., Khurana, C., Erlacher, M., Dürken, M., Linke, C., Frühwald, M., Corbacioglu, S., Claviez, A., Metzler, M., Ebinger, M., Full, H., Wiesel, T., Eberl, W., Reinhard, H., Tagliaferri, L., Allard, P., Karapanagiotou-Schenkel, I., Rother, L.-M., Beck, D., Le Cornet, L., Kulozik, A.E., German Sickle Cell Disease Registry; Sickle cell disease in Germany: Results from a national registry. *Pediatr Blood Cancer*, **2019**

81. Oswald, V., **Prokop, A.**, Boehme, J., Gressler, N., Harscheidt, F., Maas, V., Bloch, W., Baumann, FT., Daeggelmann, J.; Limited Walking Abilities and Impaired Ankle Dorsiflexion Function in Children After Intense Cancer Treatment. *Klin. Padriatr.* 231: 142-149, **2019**

82. Basova, S., Wilke, N., Koch, J. C., **Prokop, A.**, Berkessel, A., Pradel, G., and Ngwa, C. J.; Organoarsenic Compounds with In Vitro Activity against the Malaria Parasite Plasmodium falciparum. *Biomedicines*, **2020**

83. Hopff, S.M., Onambele, L.A., Brandenburg, M., Berkessel, and **Prokop, A.**; Discovery of a cobalt (III) salen complex that induces apoptosis in Burkitt like lymphoma and leukemia cells, overcoming multidrug resistance in vitro. *Bioorganic Chemistry*, 104, **2020**

84. Däggelmann, J., **Prokop, A.**, Lösse, V., Maas, V., Otten, S., Bloch, W.; Indoor Wall Climbing with Childhood Cancer Survivors: An Exploratory Study on Feasibility and Benefits. *Klin. Padiatr.* 232: 159-165. **2020**
85. Rössler, R., Baselga, E., Davila, V., Celis, V., Diociaiuto, A., Hachem, ME., Mestre, S., Häberli, D., **Prokop, A.**, Hanke, C., Loichinger, W., Quere, I., Baumgartner, I., Niemeyer, C., Kapp, F.; Severe adverse events during sirolimus “off label” therapy for vascular anomalies. *Pediatric Blood & Cancer.* **2020**
86. Daeggelmann, J., **Prokop, A.**, Loesse, V., Otten, S., Maas, V., Bloch, W., Oswald, V.; Implementing sustainable physical activity opportunities in pediatric oncology – Five-year experience of a group-based exercise program. *German Journal of Sports Medicine,* **2021**
87. Hopff, S.M., Onambele, L.A., Brandenburg, M., Berkessel, A., **Prokop, A.**; Sensitizing multidrug-resistant leukemia cells to common cytostatics by an aluminium-salen complex that has high-apoptotic effects in leukemia, lymphoma and mamma carcinoma cells. *Biometals,* **2021**
88. Daeggelmann, J., Otten, S., **Prokop, A.**, Maas, V., Streckmann, F., Bloch, W., Oswald, V.; Feasibility of a combined supervised and home-based whole-body vibration intervention in children after inpatient oncological treatment. *Sport Sci Health,* **2021**
89. Otten, S., Bischoff, C., **Prokop, A.**, Oswald, V., Maas, V., Bloch, W., Streckmann, F., Däggelmann, J.; Machbarkeit eines kind- und jugendgerechten manualgestützten Sensomotoriktrainings nach einer pädiatrisch-onkologischen Erkrankung. **Submitted 2021**
90. Daeggelmann, J., Otten, S., Lösse, V., **Prokop, A.**, Maas, V., Waltz, T., Jung, L., Bloch, W., Oswald, V.; Bewegungsförderung während der kideronkologischen Akuttherapie - Erfahrungen aus vier Jahren stationärer Sporttherapie. *Monatsschrift Kinderheilkunde,* **2021**

91. Hopf, S.M., Wang, Q., Frias, C., Ahrweiler, M., Wilke, Ni., Wilke, Na., Berkessel, A., and **Prokop, A.**; A metal-free salalen ligand with anti-tumor and synergistic activity in resistant leukemia and solid tumor cells via mitochondrial pathway. *Journal of Cancer Research and Clinical Oncology*, **2021**

92. Kater, L., Kater, B., Jakupec, M. A., Keppler, B. K., **Prokop, A.**; KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri. *Journal of Biological Inorganic Chemistry*, **2021**

Patente:

1. **Prokop, A.**, Wieder, T., Daniel, P. T. and Schmalz, H-G.; Substances for use in therapy of diseases that are caused by highly proliferative cells.

7.4.2001, *German patent* DE, No. 10117479.9 (*PRIO*)

6.4.2002, PCT, No. WO 02/080923 A1

7.10.2003 PCT, No. 2002-578962

28.7.2004 JP,, US, EP, AT, CH, DE, FR, GB, IE, IT, SE, No. 02742877.0

2. **Prokop, A.**, Wieder, T., Velcicky, J. and Schmalz, H-G.; New derivatives of nucleosides inducing apoptosis for use in therapy of diseases that are caused by highly proliferative cells. 10.2.2003, *German patent*, No. DE 10305575.4

10.2.2004, PCT/EP04/01212

3. **Prokop, A.**, Wieder, T. and Riepl, H.; Derivates of Tryptanthrine for use in therapy of diseases that are caused by highly proliferative cells.

4.4.2003, *German patent*, No. DE 10315654.2

1.4.2004, PCT/EP2004/003467

4. **Prokop, A.**, Selig, A., Franke, D., Gansäuer, A.; Carbonyl-substituierte Titanocene, 17.11.2006, *German patent* DE 10 054 690.3-44 19.11.2007, PCT/EP2007/062511 19.11.2007, US 11/942,659

5. **Prokop, A.**, Tatarskiy, V.; Kupfer-Organokomplexe, deren Verwendung als Antitumormittel und zum Schutz gesunden Gewebes vor ionisierender Strahlung, 22.2.2008, *European patent* No: EP 08 151 840.9
6. Sheshbaradaran H; **Prokop A.**, Baerga R. Cobb J. Valiahdi M. S. Lee, S., Keppler B.; Method for treating hematological cancers; 09.05.2013 *United States Patent* US20130116225
7. **Prokop, A.**, Schmalz, H.-G., Pharmaceutical composition for the therapy of diseases caused by highly proliferating cells. 2015, *European Patent*, PCT/EP2016/054538, 3.3.2016

Kurzveröffentlichungen/Poster:

1. Daniel, P.T., **Prokop, A.**, Wieder, T., Sturm, I., Eßmann, F., Seeger, K., Wuchter, C., Ludwig, W.-D., Dörken, B., and Henze, G., Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2- ratio and loss of spontaneous caspase-3 processing in vivo, *Blood*, 2000
2. Lode, H.N., Huebener, N., Zeng, Y., Wrasidlo, W., Gaedicke, G., Henze, G., Wieder, T., Daniel, P.T., and **Prokop, A.**, Treatment of CD19⁺ leukemia by targeted calicheamicin theta specifically eradicates Established disease, *Blood*, 2003, 102 (11), 621
3. Daniel, P.T., Müller, A., Belka, C., **Prokop, A.**, Schulze-Osthoff, K. and Dörken, B., Mechanism of cell death induction by adenine deoxinucleosides fludarabine and cladribine: Differential requirement of caspase-9, *Blood*, 2003, 102 (11), 592.
4. Lange, B., **Prokop, A.**, Wieder, T., Schröder, U., Henze, G., Gaedicke, G., Zeng, Y., Huebener, N. Wrasidlo, W., Shabat, D. and Lode, H.N., Mechanisms of pro-VP-16-mediated anti-tumor effects, *Blood*, 2003, 102 (11), 859
5. **Prokop, A.**, Wieder, T., Schlawe, D., Lode, H., Henze, G., Daniel, P.T. and Schmalz, H.G., Iron containing nucleosides as new cytostatic substances for cancer and leukemia therapy, especially for therapy of relapsed ALL in childhood, *Blood*, 2004, 104, 574

6. Tata, P.S., **Prokop, A.**, Riepl, H., Kayser, O., Radam, E., Kropp, E. and Kiderlen, A.F., *In vitro* efficacy of established and novel pharmaceutical agents against *Balamuthia mandrillaris* ameba, 14. Japanese-German symposium on protozoan diseases, Düsseldorf, Germany, 20.9. – 24.9.2004
7. **Prokop, A.**, Bagci, B., Lingfeld, G., Badiali, L., Garbrecht, K., Mietzsch, U., Wieder, T., Daniel, P.T. and Henze, G. Sensitivity of Childhood Acute Lymphoblastic Leukemia (ALL) to Idarubicin Is Significantly Higher Than to Daunorubicin Treatment Based on Ex Vivo Apoptosis Induction. *Blood*; 104: 4495; **2004**
8. **Prokop, A.**, Frias, C., Henze, G., Sadolinnaya, S. and Tatarskiy, V. Copper-Complexed Melphalan (MOC*M), a Member of a New Class of Anti-Leukemic and Anti-Tumouric Substances for Treatment of Primary and Relapsed Acute Lymphoblastic Leukemia in Childhood. *Blood*, 106: 4457; **2005**
9. **Prokop, A.**, Bagci, B., Lingfeld, G., Badiali, L., Mietzsch, U., Wieder, T., Daniel P.T. and Henze, G., Sensitivity of childhood acute lymphoblastic leukemia (ALL) to Idarubicin is significantly higher than to Daunorubicin treatment based on *ex vivo* apoptosis induction, *6 th Symposium of leukemia and lymphoma, Amsterdam, Netherlands, 2005*
10. Seifert, G., Jesse, P., Laengler, A., Henze, G., Lode H. N., **Prokop, A.**, Effective induction of apoptosis by Mistletoe plant extracts in an acute lymphoblastic leukemia model, *Blood*, 108: 1880; **2006**
11. **Prokop, A.**, Eissmann, M., Jesse, P., Henze, G., James, P., Neudoerfl, J., Schmalz, H.-G. Ferrocenyl Nucleoside Analogs, a New Class of Cytostatic Drugs, Overcome Multiple Drug Resistance in Acute Lymphoblastic Leukemia Ex Vivo. *Blood*, 108: 4404; **2006**
12. Katik, B., Selig, A., Velder, J., Shults, E.E., Wieder, T., Henze, G., Schmalz, H.-G., **Prokop, A.**, New Pinostilbene Analogues Overcome Anthracycline Resistance in Acute Lymphoblastic Leukemia Ex Vivo. *Blood*, 108: 4403; **2006**
13. Selig, A., Wagner, L., Winkler, I., Lauterbach, T., Gansäuer, A. and **Prokop, A.**, Carbonyl-substituted Titanocenes as new cytostatic agents against lymphoma and leukemia in childhood, *Blood*, 110: 4208; **2007**

14. Jesse, P., Mottke, G., Fulda, S., Seifert, G., Henze, G. and **Prokop, A.**, Apoptosis Induced by Extracts of *Helleborus Niger* in Different Lymphoma and Leukemia Cell Lines and Primary Lymphoblasts of Children with ALL Is Independent of Smac- Overexpression and Executed via the Mitochondrial Pathway, *Blood*, 110: 4215; **2007**
15. Franke, J. C., **Prokop, A.**, Schlawe, D., Hans-Günther Schmalz, H.-G., Fecker, L.F. and Eberle, J.. The new iron-containing nucleoside analogue N69 triggers apoptosis in human melanoma cells by a caspase-independent way, ADF, Frankfurt, **2007**
16. Seifert, G., Jesse, P., Laengler, A., Lode, H.N., **Prokop, A.**, Henze, G.: Therapeutische Wirksamkeit von Mistelextrakten *in vitro* und *in vivo* in einem Leukämiemodell durch Apoptoseinduktion. Mistletoe plant extracts have therapeutic activity against acute lymphoblastic leukemia *in vitro* and *in vivo* by induction of apoptosis. 4. Mistelsymposium, D66620 Nonnweiler, 9.11.**2007**
17. Seifert, G., Jesse, P., Längler, A., Henze, G., **Prokop, A.**, Lode, H., Experimental therapeutic efficacy of mistletoe plant extracts in acute lymphoblastic leukemia, DKK, **2007**
18. **Prokop, A.**, Eissmann, M., Kater, B., Henze, G., Eberle, J., Geilen, C.C., Franke, J., James, P., Neudörfl, J., and Schmalz, H.G.; New pan-anti-tumor Ferrocenyl nucleoside analogues overcome multiple drug resistance in malignant cells *in vitro* and *ex vivo*. 1. ICDDD, Dubai, World Trade Center, 4.-7.2.**2008**
19. **Prokop, A.**, Wagner, L., Selig, A., Kater, L., Winkler, I., Lauterbach, T., and Gansäuer, A.; Carbonyl-substituted Titanocenes, a new class of cytostatic agents against lymphoma and leukemia in childhood. 1. ICDDD, Dubai, World Trade Center, 4.-7.2.**2008**
20. Franke, J. C., **Prokop, A.**, Schlawe, D., Hans-Günther Schmalz, H.-G. and Eberle, J. The iron-containing nucleoside analogue N69 induces apoptosis in human melanoma cells by a caspase-independent way and cytochrome c release, JCF, Luxemburg, **2008**
21. Franke, J. C., **Prokop, A.**, Schlawe, D., Hans-Günther Schmalz, H.-G. and Eberle, J.; The iron-containing nucleoside analogue N69 efficiently induces apoptosis in human melanoma cells by activating new pathways enclosing lysosomal activation, ADF, Erlangen, **2008**
22. **Prokop, A.**, Eissmann, M., Kater, B., Henze, G., Eberle, J., Geilen, C.C., James, P., and Schmalz, H.-G.; Ferrocenyl nucleoside analogues, a new class of pan-anti-tumor agents,

overcome multiple drug resistance in malignant cells *in vitro* and *ex vivo*. Symposium on Medicinal Organometallic Chemistry (DFG), St. Martin, Germany, 2.5. – 5.5.2008

23. **Prokop, A.**, Wagner, L., Selig, A., Kater, L., Winkler, I., Lauterbach, T., Gansäuer, A.; A new class of cytostatic agents: Carbonyl-substituted Titanocenes against lymphoma and leukemia in childhood; Symposium on Medicinal Organometallic Chemistry (DFG), St. Martin, Germany, 2.5. – 5.5.2008

24. Jesse, P., Mottke, G., Henze, G. and **Prokop, A.**; Apoptosis Induced by Helleborus Niger In Primary Cells of Children with ALL or AML And Different Cancer Cell Lines Is Executed via the Mitochondrial Pathway in Bcl-2 Dependent Manner. Jahrestagung der Gesellschaftanthroposophischer Ärzte, Kassel, Germany, 2.-6.4.2008

25. Jesse, P., Riepl, H., Wieder, T. and **Prokop, A.**; The Synthetic Analogue of Plant Colorant Tryptanthrin, NT1, Induces Apoptosis *In Vitro*, *Ex Vivo* and *In Vivo* in CD95-Dependent Manner in Pediatric Leukemia and Lymphoma Sensitizing Malignant Cells against Cytostatic Drugs via Downregulation of XIAP, *Blood*, ASH San Francisco, 6.12.2008

26. Lee, S.-Y., Hille, A., Frias, C., Henze, G., Gust, R., **Prokop, A.**; New iron and nickel salophenes with anticancer activity overcome drug resistance in malignant cells. *DFG-Konferenz FOR 630*, Kaiserslautern, 2009

27. Kater, B., Hunold, A., Schmalz, H.-G., Kater, L., Onambele, L., Bonitzki, B., Henze, G., Eberle, J., **Prokop, A.**; A novel Ferrocenyl analogue induces apoptosis in cancer cells and overcomes mechanisms of drug resistance. *DFG-Konferenz FOR 630*, Kaiserslautern, 2009

28. Onambele, L. A., Hoffmann, N., Schmalz, H.-G., Kater, L., Kater, B., Eberle, J., **Prokop, A.**; Effects of a novel apoptosis-inducing cobalt organo-complex on lymphoma, leukemia and melanoma cells *in vitro*. *DFG-Konferenz FOR 630*, Goslar, 2010

29. Lee, S.-Y., Hille, A., Frias, C., Kater, L., Kater, B., Gust, R., **Prokop, A.**; [Fe^{III} salophene(Cl)], a novel iron salophene complex with high antitumor activity, induces apoptosis via the intrinsic pathway and overcomes drug resistance in malignant lymphoma and leukemia cells. *DFG-Konferenz FOR 630*, Goslar, 2010

30. **Prokop, A.**, Zadolinnaya, S., Frias, C., Valeriy Tatarskiy, V.; A novel metal complex with potent antitumor activity *in vivo* and in human. *ASCO*, 2011, Chicago

31. Beulertz, J., **Prokop, A.**, Zopf, E., Zimmer, P., Bloch, W., Baumann, F.T.; Establishment of a specific and individualized exercise program for children following intensive oncological treatment. *European Review of Aging and Physical Activity*; **2012**
32. Beulertz, J., Bloch, W., **Prokop, A.**, Baumann, F.T.; Einfluss eines zielgerichteten und individualisierten Sportprogramms auf die motorische Leistungsfähigkeit und gesundheitsbezogene Lebensqualität krebskranker Kinder und Jugendlicher – erste Ergebnisse. *Monatsschrift Kinderheilkunde*. **2013**; 161.
33. Beulertz, J., **Prokop, A.**, Zopf, E., Zimmer, P., Bloch, W., Baumann, F.T.; Establishment of a specific and individualized exercise program for children following intensive oncological treatment. Abstract. *European Review of Aging and Physical Activity*. **2013**, 10: 66.
34. Oehninger, L., Spreckelmeyer, S., Holenya, P., Küster, N., **Prokop, A.**, Wölfl, S., Ott, I.; Insights into the chemical biology of rhodium(I) N-heterocyclic carbene complexes as anticancer agents. *International Symposium on Bioorganometallic Chemistry – ISBOMC* **ISBOMC 2014**, 22. – 25.7.2014 in Wien
-
35. Serebryanskaya, T., Ivashkevich, L. Lyakhov, A., **Prokop, A.**, Ott, I. ; Tetrazole-based gold(I) complexes as a new group of anticancer agents. *Trends in Inorganic Chemistry – TINC* **2014**, 22.5.2014 in Lund, Sweden
36. Schmidt, C., Misgeld, R., **Prokop, A.** and Ott, I.; Halogenated Gold(I) N-heterocyclic Carbene Complexes: Biodistribution, Cytotoxicity and Thioredoxin Reductase Inhibition. *13th International Symposium on Applied Bioinorganic Chemistry (ISABC)*, Galway, Ireland (12-15 June **2015**)
37. Abodo Onambele, L., Riepl, H., Fischer, R., Pradel, G., **Prokop, A.**, and Aminake, M. N.; Evaluation of antiplasmodial activity of tryptanthrin derivatives. *53th international congress of medicinal plants and natural product research*, August **2015**

38. Rustler, V., Baumann, F.T., Bloch, W., **Prokop, A.** und Beulertz, J.; Einfluss einer 6-monatigen, gruppenbasierten Sportintervention auf die motorische Leistungsfähigkeit krebskranker Kinder und Jugendlicher nach stationärer, medizinischer Therapie. *Deutsche Vereinigung der Sportwissenschaften-Hochschultag in Mainz*, 30.9. – 2.10. **2015**
39. Rustler, V., Prokop, A., Beulertz, J., Streckmann, F., Bloch, W., Baumann, F.T.; Feasibility and Effects of whole-body vibration training for inpatient childhood cancer patients undergoing chemotherapy: a protocol of the KiVi study. *Deutsche Krebskongress in Berlin*, 24. - 27. 2. **2016**
40. Rustler, V., **Prokop, A.**, Däggelmann, J., Streckmann, F., Harscheid, F., Gressler, N., Bloch, W., Baumann, F.T.; Vibrationstraining für onkologisch erkrankte Kinder und Jugendliche nach Abschluss der stationären Akuttherapie – Praxiserfahrungen. Netzwerktreffen ActiveOncoKids, *Heidelberg*, 8.–10.9. **2016**
41. Lehnen, U., Kellner, M., Gottschlich, M., **Prokop, A.**, Guggemos, A., Deckert, M., Stenzel, M.; Sinterungsfraktur eines singulären Brustwirbelkörpers als Erstmanifestation einer akuten lymphoblastischen Leukämie (ALL). *GPR in Stuttgart*, 15.–17.9. **2016**
42. Rustler, V., **Prokop, A.**, Bloch, W., Streckmann, F., Baumann, F., und Däggelmann, J.; Vibrationstraining als innovative Trainingsform für krebserkrankte Kinder und Jugendliche während der medizinischen Therapie. *IMPULSE* Wissenschaftsmagazin der Deutschen Sporthochschule Köln, 01/**2017**
43. Rustler, V., **Prokop, A.**, Böhme, J., Scheiner, H., Gressler, N., Bloch, W.,¹, Baumann, F.T., und Däggelmann, J.; Teilnahmequoten einer stationären Sporttherapie für krebserkrankte Kinder und Jugendliche unter Chemotherapie. Deutscher Olympischer Sportärztekongress *DGSP in Hamburg*, 05/**2018**
44. Stein, A., Thomopoulou, P., Schulte, T., Gigant, B., **Prokop, A.**, Schmalz, H.-G.; Adventures in the synthesis and biological evaluation of novel “reactive” Colchicine-derived compounds. *ISCNP in Athen*, 11/**2018**

45. Oswald, V., **Prokop, A.**, Otten, S., Maas, V., Streckmann, F., Bloch, W., Krumbach, J., Däggelmann, J.; Safety of a combined supervised and home-based whole-body vibration intervention for childhood cancer survivors. *Deutscher Krebskongress in Berlin, 02/2020*

46. Otten,S., **Prokop, A.**, Oswald, V., Maas, V., Streckmann, F., Bloch, W., Krumbach, J., Willibald, S., Däggelmann, J.; Effects of a whole-body vibration intervention in children and adolescents after inpatient anticancer therapy on ankle dorsiflexion function and balance control. *Deutscher Krebskongress in Berlin, 02/2020*